An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Better Therapeutics (NASDAQ: BTTX) will host a conference call and webcast on July 28, 2022, at 8:30 a.m. ET, to discuss the results of its pivotal clinical trial of BT-001 for type 2 diabetes after 180 days of treatment. The management team will be joined by Marc Bonaca, MD, MPH, from the University of Colorado. This trial is part of their initiative to develop nutritional cognitive behavioral therapy aimed at addressing cardiometabolic diseases.
Positive
The upcoming conference call indicates transparency and engagement with investors.
The pivotal trial results could signal significant advancements for BT-001 in treating type 2 diabetes.
Negative
None.
Conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET
SAN FRANCISCO--(BUSINESS WIRE)--
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics management team will be joined by Marc Bonaca, MD, MPH, Professor of Medicine and Director of Vascular Research at University of Colorado.
The live conference call may be accessed by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) and referring to conference ID: 4326594. All participants are encouraged to dial-in 10 minutes prior to the start time. The live webcast may be accessed by visiting the event page here. A replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website: www.bettertx.com.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
What is the purpose of the upcoming conference call for Better Therapeutics on July 28, 2022?
The conference call will discuss the results from the pivotal clinical trial of BT-001 for type 2 diabetes.
Who will participate in the Better Therapeutics conference call regarding BT-001?
Members of Better Therapeutics' management team will be joined by Marc Bonaca, MD, MPH, from the University of Colorado.
What are the expected outcomes from the BT-001 clinical trial results?
The clinical trial results could indicate the effectiveness of BT-001 in treating type 2 diabetes, impacting its market potential.
How does Better Therapeutics' approach address cardiometabolic diseases?
Better Therapeutics uses a prescription digital therapeutic approach, focusing on cognitive behavioral therapy to tackle the root causes of cardiometabolic diseases.
